AbbVie CEO Summoned to Congress—Again—to Answer Questions on Humira Pricing, Patenting

Accused of forming a patent thicket around its top-seller Humira and cancer blockbuster Imbruvica, AbbVie has faced repeated pressure from the House Committee on Oversight and Reform to layout its pricing and patenting strategies. With that information now in hand, the committee is putting AbbVie’s helmsman in the hot seat.



Photo Credits: AbbVie

Recent Posts